PL2952191T3 - Apomorfina w postaci do podawania podjęzykowego - Google Patents

Apomorfina w postaci do podawania podjęzykowego

Info

Publication number
PL2952191T3
PL2952191T3 PL15175258T PL15175258T PL2952191T3 PL 2952191 T3 PL2952191 T3 PL 2952191T3 PL 15175258 T PL15175258 T PL 15175258T PL 15175258 T PL15175258 T PL 15175258T PL 2952191 T3 PL2952191 T3 PL 2952191T3
Authority
PL
Poland
Prior art keywords
sublingual apomorphine
apomorphine
sublingual
Prior art date
Application number
PL15175258T
Other languages
English (en)
Inventor
Anthony John Giovinazzo
David Bruce Hedden
Marc L. De Somer
Nathan John Bryson
Original Assignee
Sunovion Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43309244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2952191(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sunovion Pharmaceuticals Inc. filed Critical Sunovion Pharmaceuticals Inc.
Publication of PL2952191T3 publication Critical patent/PL2952191T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
PL15175258T 2009-06-12 2010-06-11 Apomorfina w postaci do podawania podjęzykowego PL2952191T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18644509P 2009-06-12 2009-06-12
EP10786915.8A EP2442650B1 (en) 2009-06-12 2010-06-11 Sublingual apomorphine
PCT/US2010/038336 WO2010144817A1 (en) 2009-06-12 2010-06-11 Sublingual apomorphine
EP15175258.1A EP2952191B1 (en) 2009-06-12 2010-06-11 Sublingual apomorphine

Publications (1)

Publication Number Publication Date
PL2952191T3 true PL2952191T3 (pl) 2019-02-28

Family

ID=43309244

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10786915T PL2442650T3 (pl) 2009-06-12 2010-06-11 Apomorfina do podawania podjęzykowego
PL15175258T PL2952191T3 (pl) 2009-06-12 2010-06-11 Apomorfina w postaci do podawania podjęzykowego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10786915T PL2442650T3 (pl) 2009-06-12 2010-06-11 Apomorfina do podawania podjęzykowego

Country Status (20)

Country Link
US (10) US9044475B2 (pl)
EP (3) EP2442650B1 (pl)
JP (6) JP5760295B2 (pl)
KR (5) KR20170027711A (pl)
CN (1) CN102480958B (pl)
AU (4) AU2010259971C1 (pl)
BR (1) BR112012000204B8 (pl)
CA (1) CA2765291C (pl)
DK (2) DK2442650T3 (pl)
EA (1) EA025054B1 (pl)
ES (2) ES2554626T3 (pl)
HK (2) HK1171340A1 (pl)
HU (1) HUE028121T2 (pl)
IL (2) IL216923A (pl)
MX (1) MX2011013260A (pl)
NZ (1) NZ597237A (pl)
PL (2) PL2442650T3 (pl)
PT (2) PT2952191T (pl)
WO (1) WO2010144817A1 (pl)
ZA (1) ZA201109208B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
WO2010086989A1 (ja) 2009-01-29 2010-08-05 日東電工株式会社 口腔内フィルム状基剤及び製剤
ES2554626T3 (es) 2009-06-12 2015-12-22 Cynapsus Therapeutics Inc. Apomorfina sublingual
JP5751868B2 (ja) * 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
ES2791715T3 (es) 2010-12-16 2020-11-05 Sunovion Pharmaceuticals Inc Películas sublinguales
EP2744343B1 (en) 2011-08-17 2021-03-10 Board Of Regents, The University Of Texas System Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
JP5841433B2 (ja) 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
GB201217419D0 (en) * 2012-09-28 2012-11-14 Innotesto Bvba Improvements in or relating to oromucosal apomorphine compositions
EP3524247A1 (en) * 2013-11-11 2019-08-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
JP7211706B2 (ja) * 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
US10398655B2 (en) 2016-02-18 2019-09-03 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
BR112019012683B1 (pt) 2016-12-22 2023-11-07 Nissan North America, Inc. Sistema remoto para um veículo autônomo
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
DE102017108611A1 (de) * 2017-04-21 2018-10-25 Technische Universität Clausthal Energie-effizientes lösungsmittelfreies Verfahren zur Herstellung von Aminosäure-Metallchelaten
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
CN112272554A (zh) * 2018-02-22 2021-01-26 艾维奥尔股份有限公司 经粘膜的膜组合物及其制备和使用方法
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
US11648197B2 (en) * 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
US20220241156A1 (en) 2019-06-27 2022-08-04 Sunovion Pharmaceuticals Inc. Child-resistant dispensers for thin strip medications
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate
WO2022013869A1 (en) * 2020-07-15 2022-01-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oral cavity polymeric delivery systems
CN115671106B (zh) * 2021-07-21 2024-03-19 广州新济药业科技有限公司 吗啡的应用

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1234123A (en) 1915-08-25 1917-07-24 Charles L Bond Weighing device.
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4614545A (en) 1985-08-15 1986-09-30 The Dow Chemical Company Hydroxypropyl methyl cellulose thickening agents for organic liquids
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
DE4018247A1 (de) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0644746T3 (da) * 1992-06-11 1999-12-20 Theratech Inc Anvendelse af glycerin til moderering af transdermal lægemiddelafgivelse
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
WO1995005416A2 (en) 1993-08-19 1995-02-23 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
DE69514794T2 (de) 1994-04-22 2000-07-27 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
JPH0834731A (ja) * 1994-07-26 1996-02-06 T T S Gijutsu Kenkyusho:Kk グラニセトロン含有経皮吸収型製剤
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5523090A (en) 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
US6667056B2 (en) 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6087362A (en) 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
CA2349406C (en) * 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE19954245A1 (de) 1999-11-11 2001-07-19 Lohmann Therapie Syst Lts Mehrschichtige filmförmige Zubereitung aus hydrophilen Polymeren zur schnellen Freisetzung von Wirkstoffen
DE19954421A1 (de) 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen
BR0012822A (pt) * 1999-12-30 2004-03-09 Tap Holdings Inc Formulação farmacêutica, e, forma de dosagem em tablete
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
ES2326209T3 (es) 2000-10-27 2009-10-05 Baxter Healthcare S.A. Produccion de microesferas.
US6756051B1 (en) 2000-11-15 2004-06-29 Li-Lan H. Chen Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
US20030022912A1 (en) * 2001-02-08 2003-01-30 Martino Alice C. Rapid-onset medicament for treatment of sexual dysfunction
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
JP2003006170A (ja) * 2001-06-20 2003-01-10 Hitachi Ltd 複数計算機環境でのプログラム実行方法
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US20080050422A1 (en) 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
US20060004190A1 (en) 2002-03-19 2006-01-05 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US6566359B1 (en) * 2002-05-20 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College 2,4,6-trimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid esters as neuroprotective drugs
DE10224612A1 (de) 2002-06-04 2003-12-24 Lohmann Therapie Syst Lts Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung
GB0221711D0 (en) 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
EA200500764A1 (ru) * 2002-11-12 2005-12-29 Тева Фармасьютикал Индастриес Лтд. Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
US9561182B2 (en) 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
AU2003295577A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Edible film for relief of cough or symptoms associated with pharyngitis
ATE553746T1 (de) 2003-01-30 2012-05-15 Monosolrx Llc Verfahren zur herstellung eines dünnen films, thermolabile wirkstoffe enthaltend
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
WO2004096125A2 (en) * 2003-04-14 2004-11-11 Shire Laboratories, Inc. Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
AU2004319243B2 (en) 2003-05-28 2010-06-03 Aquestive Therapeutics, Inc. Polyethylene oxide-based films and drug delivery systems made therefrom
CN1460476A (zh) * 2003-06-08 2003-12-10 胡秀爱 可调释药速率的阿扑吗啡舌下滴丸制剂
ES2654062T3 (es) 2003-07-24 2018-02-12 Glaxosmithkline Llc Películas de disolución oral
US9248146B2 (en) 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
EP1708685B1 (en) 2003-12-31 2011-03-09 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering oxycodone
WO2005074894A1 (en) 2004-01-30 2005-08-18 Corium International Rapidly dissolving film for delivery of an active agent
KR20130006523A (ko) 2004-02-17 2013-01-16 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
JP4413665B2 (ja) 2004-03-19 2010-02-10 救急薬品工業株式会社 口腔内粘膜フィルム剤
EP1737458A4 (en) 2004-04-13 2010-08-04 Mclean Hospital Corp R (-) - 11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF
EP1799453B1 (en) 2004-09-30 2012-09-05 MonoSolRX, LLC Multi-layer films having uniform content
RU2283650C1 (ru) * 2005-02-24 2006-09-20 Закрытое Акционерное Общество "Канонфарма Продакшн" Твердая лекарственная форма для улучшения мужской эректильной функции
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102005041860A1 (de) 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2007030754A2 (en) 2005-09-09 2007-03-15 Monosolrx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
EP1971312A1 (en) 2005-12-06 2008-09-24 MonoSol Rx LLC Topical film compositions for delivery of actives
CN101346135A (zh) * 2005-12-27 2009-01-14 莫诺索尔克斯有限公司 用于活性剂递送的已调节pH的膜
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
HUE027395T2 (hu) 2006-07-21 2016-10-28 Biodelivery Sciences Int Inc Eszközök nyálkahártyán keresztül történõ bejuttatására, javított felszívódással
KR101448050B1 (ko) 2006-10-02 2014-10-14 랍테크 게젤샤프트 퓌르 테히놀로기슈 포르슝 운트 엔트빅클룽 엠베하 점막 비점착성 필름 제형
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US7843456B2 (en) * 2007-06-29 2010-11-30 Microsoft Corporation Gradient domain editing of animated meshes
CA2702614A1 (en) 2007-10-19 2009-04-23 Innozen, Inc. Composition for administering an active ingredient and method for making and using the same
EP2210595A1 (en) * 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
CN102459338A (zh) 2009-05-08 2012-05-16 霍夫曼-拉罗奇有限公司 人源化抗egfl7抗体及其使用方法
ES2554626T3 (es) 2009-06-12 2015-12-22 Cynapsus Therapeutics Inc. Apomorfina sublingual
ES2791715T3 (es) 2010-12-16 2020-11-05 Sunovion Pharmaceuticals Inc Películas sublinguales
GB201217419D0 (en) 2012-09-28 2012-11-14 Innotesto Bvba Improvements in or relating to oromucosal apomorphine compositions

Also Published As

Publication number Publication date
AU2019200308A1 (en) 2019-02-07
US20210322403A1 (en) 2021-10-21
DK2952191T3 (en) 2018-12-10
AU2010259971A1 (en) 2012-01-19
CN102480958A (zh) 2012-05-30
US9669019B2 (en) 2017-06-06
JP2019123732A (ja) 2019-07-25
US9326981B2 (en) 2016-05-03
CA2765291A1 (en) 2010-12-16
KR20150094648A (ko) 2015-08-19
JP6267254B2 (ja) 2018-01-24
JP6506381B2 (ja) 2019-04-24
AU2010259971B2 (en) 2016-10-27
CN102480958B (zh) 2015-08-19
BR112012000204A8 (pt) 2018-06-12
HUE028121T2 (en) 2016-11-28
KR20190103472A (ko) 2019-09-04
NZ597237A (en) 2014-02-28
HK1218630A1 (zh) 2017-03-03
US10420763B2 (en) 2019-09-24
US20150216859A1 (en) 2015-08-06
US9669020B2 (en) 2017-06-06
EP2442650A1 (en) 2012-04-25
KR20170027711A (ko) 2017-03-10
AU2021201259A1 (en) 2021-03-18
IL253965B (en) 2022-06-01
AU2017200329A1 (en) 2017-02-23
KR20180069100A (ko) 2018-06-22
US20160101101A1 (en) 2016-04-14
KR102086311B1 (ko) 2020-03-06
US20160089367A1 (en) 2016-03-31
AU2017200329B2 (en) 2018-11-08
DK2442650T3 (en) 2015-12-07
US9669021B2 (en) 2017-06-06
EA025054B1 (ru) 2016-11-30
MX2011013260A (es) 2012-02-28
EP2442650B1 (en) 2015-08-26
JP2018083820A (ja) 2018-05-31
JP6141354B2 (ja) 2017-06-07
JP5760295B2 (ja) 2015-08-05
EP2952191A1 (en) 2015-12-09
ZA201109208B (en) 2013-09-25
PL2442650T3 (pl) 2016-01-29
US20160095851A1 (en) 2016-04-07
US20160089328A1 (en) 2016-03-31
US20160081914A1 (en) 2016-03-24
IL216923A (en) 2017-08-31
IL216923A0 (en) 2012-02-29
EA201270012A1 (ru) 2012-07-30
EP2442650A4 (en) 2012-11-14
KR102017009B1 (ko) 2019-09-02
HK1171340A1 (zh) 2013-03-28
CA2765291C (en) 2016-03-08
AU2019200308B2 (en) 2020-11-26
JP6770126B2 (ja) 2020-10-14
JP2015199743A (ja) 2015-11-12
BR112012000204A2 (pt) 2016-11-01
ES2554626T3 (es) 2015-12-22
PT2442650E (pt) 2015-12-18
EP2952191B1 (en) 2018-08-22
EP3434270A1 (en) 2019-01-30
US9669018B2 (en) 2017-06-06
IL253965A0 (en) 2017-10-31
ES2699077T3 (es) 2019-02-07
BR112012000204B1 (pt) 2020-11-24
US20110111011A1 (en) 2011-05-12
US20180289699A1 (en) 2018-10-11
KR20120042836A (ko) 2012-05-03
JP2016147882A (ja) 2016-08-18
PT2952191T (pt) 2018-11-30
BR112012000204B8 (pt) 2021-05-25
JP2021001209A (ja) 2021-01-07
WO2010144817A1 (en) 2010-12-16
US9044475B2 (en) 2015-06-02
US20200030315A1 (en) 2020-01-30
AU2010259971C1 (en) 2017-02-16
JP2012530066A (ja) 2012-11-29

Similar Documents

Publication Publication Date Title
IL253965A0 (en) Sublingual apomorphine
HK1168791A1 (en) Substituted imidazoquinoxalines
EP2483254A4 (en) NEW COMPOUNDS
IL213794A0 (en) Novel uses
ZA201109437B (en) Novel azabicyclohexanes
ZA201105535B (en) Novel tricyanoborates
HK1174617A1 (en) Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts -1----2---
EP2456311A4 (en) SUBSTITUTED IMIDASOTRIAZINES
ZA201108565B (en) Substituted piperidnes
EP2509287A4 (en) SLIDING AND TILTING MECHANISM
EP2448583A4 (en) SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES
GB0908435D0 (en) Processes
GB2483195B (en) Novel uses
GB0904677D0 (en) Novel case
GB0916844D0 (en) Novel case
EP2448584A4 (en) Substituted 4-hydroxypropyl-5-carboxamide
GB0900924D0 (en) Instant kofta
GB2483404B (en) Hand scabbler
GB0909661D0 (en) Watercraft
GB0908544D0 (en) Downpipe
GB0912940D0 (en) Endoperoxides
GB0904353D0 (en) Novel thiazolopyrimidines
GB0912995D0 (en) Tiles cover
ZA200906707B (en) Template-fixed peptidomimetics
GB0907825D0 (en) Novel compound